{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T01:40:20Z","timestamp":1722303620182},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.cct.2024.107580","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T18:52:23Z","timestamp":1716490343000},"page":"107580","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Assessing the performance of methods for central statistical monitoring of a binary or continuous outcome in multi-center trials: A simulation study"],"prefix":"10.1016","volume":"143","author":[{"given":"Li","family":"Ge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongkai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles C.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spencer","family":"Childress","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Wildfire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.cct.2024.107580_bb0005","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1002\/(SICI)1097-0258(19991230)18:24<3435::AID-SIM365>3.0.CO;2-O","article-title":"The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials","volume":"18","author":"Buyse","year":"1999","journal-title":"Stat. Med."},{"issue":"1","key":"10.1016\/j.cct.2024.107580_bb0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/1740774507087554","article-title":"Ensuring trial validity by data quality assurance and diversification of monitoring methods","volume":"5","author":"Baigent","year":"2008","journal-title":"Clin. Trials"},{"issue":"4","key":"10.1016\/j.cct.2024.107580_bb0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/009286151104500404","article-title":"Evaluation of data entry errors and data changes to an electronic data capture clinical trial database","volume":"45","author":"Mitchel","year":"2011","journal-title":"Drug Inf. J."},{"key":"10.1016\/j.cct.2024.107580_bb0020","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/0092861512442057","article-title":"Source data verification by statistical sampling: issues in implementation","volume":"46","author":"Grieve","year":"2012","journal-title":"Drug Informat. J."},{"issue":"6","key":"10.1016\/j.cct.2024.107580_bb0025","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/2168479015586001","article-title":"Risk-based monitoring: a closer statistical look at source document verification, queries, study size effects, and data quality","volume":"49","author":"Tantsyura","year":"2015","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"2","key":"10.1016\/j.cct.2024.107580_bb0030","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1740774511427325","article-title":"The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-Centre clinical trial","volume":"9","author":"Bakobaki","year":"2012","journal-title":"Clin. Trials"},{"issue":"3","key":"10.1016\/j.cct.2024.107580_bb0035","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/1740774511402703","article-title":"Monitoring the quality of conduct of clinical trials: a survey of current practices","volume":"8","author":"Morrison","year":"2011","journal-title":"Clin. Trials"},{"issue":"1","key":"10.1016\/j.cct.2024.107580_bb0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1740774507087551","article-title":"Sensible approaches for reducing clinical trial costs","volume":"5","author":"Eisenstein","year":"2008","journal-title":"Clin. Trials"},{"issue":"9480","key":"10.1016\/j.cct.2024.107580_bb0045","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0140-6736(05)66875-4","article-title":"The good clinical practice guideline: a bronze standard for clinical research","volume":"366","author":"Grimes","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cct.2024.107580_bb0050","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ahj.2004.04.049","article-title":"Reducing the costs of phase iii cardiovascular clinical trials","volume":"149","author":"Eisenstein","year":"2005","journal-title":"Am. Heart J."},{"issue":"11","key":"10.1016\/j.cct.2024.107580_bb0055","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nrd4437","article-title":"Re-inventing clinical trials through transcelerate","volume":"13","author":"Gill","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cct.2024.107580_bb0060","first-page":"1","article-title":"Reflection paper on risk based quality management in clinical trials","volume":"44","author":"European Medicines Agency","year":"2013","journal-title":"Compl. Inspection"},{"year":"2013","author":"Food","series-title":"Guidance for Industry. Oversight of Clinical Investigations\u2014A Risk-Based Approach to Monitoring","key":"10.1016\/j.cct.2024.107580_bb0065"},{"issue":"2","key":"10.1016\/j.cct.2024.107580_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1740774513508028","article-title":"Central site monitoring: results from a test of accuracy in identifying trials and sites failing food and drug administration inspection","volume":"11","author":"Lindblad","year":"2014","journal-title":"Clin. Trials"},{"issue":"5","key":"10.1016\/j.cct.2024.107580_bb0075","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/2168479014546335","article-title":"Defining a central monitoring capability: sharing the experience of transcelerate biopharma\u2019s approach, part 1","volume":"48","author":"Wilson","year":"2014","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"1","key":"10.1016\/j.cct.2024.107580_bb0080","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/2168479015618696","article-title":"Defining a central monitoring capability: sharing the experience of transcelerate biopharma's approach, part 2","volume":"50","author":"Gough","year":"2016","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"2","key":"10.1016\/j.cct.2024.107580_bb0085","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/2168479016630576","article-title":"Statistical monitoring in clinical trials: best practices for detecting data anomalies suggestive of fabrication or misconduct","volume":"50","author":"Knepper","year":"2016","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"1","key":"10.1016\/j.cct.2024.107580_bb0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2168479015620248","article-title":"Detecting data quality issues in clinical trials: current practices and recommendations","volume":"50","author":"Knepper","year":"2016","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.cct.2024.107580_bb0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cct.2016.09.003","article-title":"Risk based monitoring (rbm) tools for clinical trials: a systematic review","volume":"51","author":"Hurley","year":"2016","journal-title":"Contemp. Clin. Trials"},{"issue":"4","key":"10.1016\/j.cct.2024.107580_bb0100","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s43441-021-00295-8","article-title":"Risk-based monitoring in clinical trials: past, present, and future","volume":"55","author":"Barnes","year":"2021","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.cct.2024.107580_bb0105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10147-015-0914-4","article-title":"Statistical challenges for central monitoring in clinical trials: a review","volume":"21","author":"Oba","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.cct.2024.107580_bb0110","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10120-015-0533-9","article-title":"Statistical monitoring of data quality and consistency in the stomach cancer adjuvant multi-institutional trial group trial","volume":"19","author":"Timmermans","year":"2016","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.cct.2024.107580_bb0115","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s43441-022-00496-9","article-title":"Risk-based monitoring in clinical trials: 2021 update","volume":"57","author":"Adams","year":"2023","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.cct.2024.107580_bib236","first-page":"1","article-title":"Good Statistical Monitoring: A Flexible Open-Source Tool to Detect Risks in Clinical Trials","author":"Wu","year":"2024","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"2","key":"10.1016\/j.cct.2024.107580_bb0120","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s43441-022-00470-5","article-title":"Does central monitoring lead to higher quality? An analysis of key risk indicator outcomes","volume":"57","author":"de Viron","year":"2023","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.cct.2024.107580_bb0125","first-page":"1","article-title":"Does central statistical monitoring improve data quality? An analysis of 1,111 sites in 159 clinical trials","author":"de Viron","year":"2024","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"5","key":"10.1016\/j.cct.2024.107580_bb0130","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1177\/1740774513494504","article-title":"Application of methods for central statistical monitoring in clinical trials","volume":"10","author":"Kirkwood","year":"2013","journal-title":"Clin. Trials"},{"issue":"2","key":"10.1016\/j.cct.2024.107580_bb0135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1740774512469312","article-title":"Central statistical monitoring: detecting fraud in clinical trials","volume":"10","author":"Pogue","year":"2013","journal-title":"Clin. Trials"},{"issue":"6","key":"10.1016\/j.cct.2024.107580_bb0140","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1740774512447898","article-title":"A statistical approach to central monitoring of data quality in clinical trials","volume":"9","author":"Venet","year":"2012","journal-title":"Clin. Trials"},{"issue":"7","key":"10.1016\/j.cct.2024.107580_bb0145","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.clinthera.2018.04.020","article-title":"Risk-based monitoring of clinical trials: an integrative approach","volume":"40","author":"Agrafiotis","year":"2018","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.cct.2024.107580_bb0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/1740774520976561","article-title":"Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: a scoping review","volume":"18","author":"Cragg","year":"2021","journal-title":"Clin. Trials"},{"issue":"8","key":"10.1016\/j.cct.2024.107580_bb0155","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/sim.1970","article-title":"Funnel plots for comparing institutional performance","volume":"24","author":"Spiegelhalter","year":"2005","journal-title":"Stat. Med."},{"issue":"30","key":"10.1016\/j.cct.2024.107580_bb0160","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1002\/sim.6294","article-title":"Linear mixed-effects models for central statistical monitoring of multicenter clinical trials","volume":"33","author":"Desmet","year":"2014","journal-title":"Stat. Med."},{"issue":"1","key":"10.1016\/j.cct.2024.107580_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19466315.2016.1164751","article-title":"Use of the beta-binomial model for central statistical monitoring of multicenter clinical trials","volume":"9","author":"Desmet","year":"2017","journal-title":"Stat. Biopharma. Res."},{"key":"10.1016\/j.cct.2024.107580_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2020.100566","article-title":"Bayesian central statistical monitoring using finite mixture models in multicenter clinical trials","volume":"19","author":"Hatayama","year":"2020","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.cct.2024.107580_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-6215-12-S1-A135","article-title":"A key risk indicator approach to central statistical monitoring in multicentre clinical trials: method development in the context of an ongoing large-scale randomized trial","volume":"12","author":"Elsa","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.cct.2024.107580_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2022.106764","article-title":"Evaluating the evaluators-developing evidence of quality oversight effectiveness for clinical trial monitoring: source data verification, source data review, statistical monitoring, key risk indicators, and direct measure of high risk errors","volume":"117","author":"Manasco","year":"2022","journal-title":"Contemp. Clin. Trials"},{"issue":"2","key":"10.1016\/j.cct.2024.107580_bb0185","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4155\/cli.14.116","article-title":"Data fraud in clinical trials","volume":"5","author":"George","year":"2015","journal-title":"Clin. Invest."},{"key":"10.1016\/j.cct.2024.107580_bb0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jclinepi.2017.03.018","article-title":"A computationally simple central monitoring procedure, effectively applied to empirical trial data with known fraud","volume":"87","author":"van den Bor","year":"2017","journal-title":"J. Clin. Epidemiol."},{"issue":"17","key":"10.1016\/j.cct.2024.107580_bb0195","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1001\/jama.2012.3424","article-title":"Characteristics of clinical trials registered in clinicaltrials. gov, 2007\u20132010","volume":"307","author":"Califf","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2024.107580_bb0200","doi-asserted-by":"crossref","first-page":"101168","DOI":"10.1016\/j.conctc.2023.101168","article-title":"Performance of four centralized statistical monitoring methods for early detection of an atypical center in a multicenter study","volume":"34","author":"Niangoran","year":"2023","journal-title":"Contemp. Clin. Trials Commun."},{"issue":"7511","key":"10.1016\/j.cct.2024.107580_bb0205","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/bmj.331.7511.267","article-title":"Are these data real? Statistical methods for the detection of data fabrication in clinical trials","volume":"331","author":"Al-Marzouki","year":"2005","journal-title":"Bmj"},{"issue":"5","key":"10.1016\/j.cct.2024.107580_bb0210","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/qshc.2005.013755","article-title":"Handling over-dispersion of performance indicators","volume":"14","author":"Spiegelhalter","year":"2005","journal-title":"BMJ Qual. Saf."},{"key":"10.1016\/j.cct.2024.107580_bb0215","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neucom.2004.11.018","article-title":"Robust bayesian mixture modelling","volume":"64","author":"Svens\u00e9n","year":"2005","journal-title":"Neurocomputing"},{"key":"10.1016\/j.cct.2024.107580_bb0220","series-title":"Proceedings of the 28th Annual International ACM SIGIR Conference on Research and Development in Information Retrieval","first-page":"573","article-title":"A geometric interpretation of r-precision and its correlation with average precision","author":"Aslam","year":"2005"},{"issue":"11","key":"10.1016\/j.cct.2024.107580_bb0225","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1016\/j.jspi.2005.03.008","article-title":"Robust estimation in the normal mixture model","volume":"136","author":"Fujisawa","year":"2006","journal-title":"J. Statist. Plan. Infer."},{"key":"10.1016\/j.cct.2024.107580_bb0230","first-page":"323","article-title":"What is the right comparison? Roc curve and trade-off between key diagnostic test errors (rocke)","author":"Pantoja-Galicia","year":"2019","journal-title":"Contem. Biostat. Biopharmaceut. Appl."},{"issue":"5","key":"10.1016\/j.cct.2024.107580_bb0235","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1177\/2168479017738981","article-title":"Rethinking the clinically based thresholds of transcelerate biopharma for risk-based monitoring","volume":"52","author":"Zink","year":"2018","journal-title":"Ther. Innov. Regul. Sci."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714424001630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714424001630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T01:24:43Z","timestamp":1722302683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714424001630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":48,"alternative-id":["S1551714424001630"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2024.107580","relation":{},"ISSN":["1551-7144"],"issn-type":[{"type":"print","value":"1551-7144"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the performance of methods for central statistical monitoring of a binary or continuous outcome in multi-center trials: A simulation study","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2024.107580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107580"}}